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Summary
 
A successful T cell immune response has two major products: effector T cells which directly or
indirectly remove the antigens, and memory T cells, which allow a faster and more efficient re-
call response when challenged by related antigens. An important issue is whether costimulatory
molecules on the antigen-presenting cells are involved in determining whether T cells will dif-
ferentiate into effector or memory cells after antigenic stimulation. To address this issue, we
have produced mice with targeted mutations of either the heat-stable antigen (HSA), or both
HSA and CD28. We show that CD28/B7 and HSA provide two alternative costimulatory
pathways for induction of immunological memory to influenza virus. Furthermore, our results
revealed that B7 is essential for the generation of effector T cells from either naive or memory
T cells, while HSA is not necessary for the generation of effector T cells. Our results demon-
strate that the induction of memory T cells and effector T cells can utilize distinct costimula-
tory molecules. These results have important implications on lineage relationship between ef-
fector and memory T cells.
 
E
 
ffector and memory T cells differ in two important as-
pects. First, by definition, effector T cells participate in
antigen clearance without further differentiation, while mem-
ory T cells have no immediate effector function. Second,
effector T cells are short-lived: anti-viral CTL effectors are
detectable in a time span of 1–2 wk after infection
 
 
 
(1), and
the majority, if not all, of the effector T cells undergo pro-
grammed cell death (2–4). Memory CTL, in contrast, ap-
pear to be long-lived in the absence of intentional antigenic
stimulation (5–7), although it is still debated whether a low
level stimulation via the T cell receptor is required for
maintenance of immunological memory (8). These differ-
ences raise an interesting possibility that the conditions re-
quired for the induction of these two functional T cell
types may be different.
Induction of significant clonal expansion of naive T cells
requires two types of biological signals (9–13). One is de-
livered by interaction of the T cell receptor with its ligand.
The other, the costimulatory signal, is delivered by a vari-
ety of molecules such as the B7 family members B7-1 (14–
17) and B7-2 (18–22) which interact both with CD28 (14)
and with CTLA4 at a higher affinity (23) on T cells, the
heat-stable antigen (HSA)
 
1
 
 (24–30), CD44 (31), and inter-
cellular adhesion molecule-1 (32, 33). Given the fact that
effector cells and memory cells can be induced by the same
antigen, we were interested in asking whether distinct co-
stimulatory molecules are utilized for the induction of these
two populations of cells.
Most in vitro studies suggest a major role for costimula-
tory molecules, particularly that of the B7 family members,
B7-1 and B7-2, in the induction of effector T cells from na-
ive T cells in vitro (34, 35). However, it is not clear whether
B7 is required for the induction of effector T cells from
memory T cells. Whereas the induction of effector T cells
in vivo has not been systematically studied with regards to
the requirement for costimulatory molecules, potent effects
of CTLA4-Ig, a fusion protein with a high affinity for B7-1
and B7-2 (36), in blocking the rejection of allogeneic (37)
or xenogeneic grafts (38) supports a major role of B7 in the
induction of effector T cells in vivo. However, it is un-
known whether induction of memory T cells requires co-
stimulation. Several recent studies suggest that T cell prim-
ing can be achieved in the absence of a B7:CD28/CTLA4
interaction (39–41). Some of the studies were interpreted
as evidence that antigen alone, if appropriately localized,
would be sufficient to prime T cells (41). However, this in-
terpretation contradicts a large collection of studies (10, 11,
42, 43) which demonstrate that engagement of T cell re-
ceptors in the absence of costimulation leads to the induc-
tion of T cell tolerance rather than immunity. An alterna-
tive possibility is that other costimulatory molecules, such
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Abbreviations used in this paper:
 
 CTLp, the precursor for cytolytic lym-
phocytes; HSA, The heat-stable antigen; WT, wild-type mice; KO, mice
with a homozygous targeted-mutation; LCMV, lymphocytic choriomen-
ingitis virus; NP, nucleoprotein of influenza virus A/JAP.
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as HSA, are sufficient to induce immunological memory
from naive T cells.
HSA is a GPI-anchored protein (44–46), and it is ex-
pressed on multiple lineages of hemapoietic and neuronal
origin (47, 48). It was implicated as a costimulatory mole-
cule when a mAb which blocks T cell proliferation and in-
duces T cell unresponsiveness in vitro, was shown to bind
HSA by expression cloning (25). Indeed, gene-transfection
experiments indicated that HSA can transfer costimulatory
activity to CHO cells (25). In addition, accumulating evi-
dence supports a role of HSA in costimulating T cells in a
variety of experimental models involving several different
types of antigen-presenting cells (APC). On B cells, HSA
and B7 appear to act synergistically in inducing clonal ex-
pansion of T cells (24–26, 29). HSA expressed on Langer-
hans cells is involved in both the induction of clonal ex-
pansion and prevention of clonal anergy of Th1 clones
(27). More recently, HSA was shown to be induced during
macrophage phagocytosis and to be critical for in vitro
priming of naive CD8 T cells (30). Furthermore, tumors
transfected with HSA induce better priming of anti-tumor
CTL responses (28).
To address the requirement for costimulatory molecules
in the induction of effector and memory CTL, we have
produced mice with a targeted mutation of the HSA gene.
We have also bred HSA-deficient mice with CD28-defi-
cient mice (39) and thereby generated mice deficient in
both HSA and CD28. We have chosen influenza virus as
the antigen because both effector and memory CTL re-
sponses can be easily detected in vivo (1). Our results dem-
onstrate that induction of effector and memory CTL uti-
lizes distinct costimulatory molecules.
 
Materials and Methods
 
Antibodies, Cell Lines, Synthetic Peptide and
Experimental Animals
 
Anti-B7-1 mAb 3A12 (18), anti-B7-2 mAb GL-1 (20), anti-
CD28 mAb 37N (41), and anti-HSA mAb antibody 20C9 (25)
were used in these studies. All mAbs were purified from hybri-
doma supernatants using a protein G column. A mixture of affin-
ity-purified normal IgG from rat and hamsters were used as con-
trol. The thymoma cell line EL4 (H-2
 
b
 
), and mastocytomas cell
line P815 (H-2
 
d
 
) were used as target cells for cytotoxicity assays.
As antigen, we synthesized a peptide according to the amino acid
sequence of a fragment of influenza virus A/JAP/57 nucleopro-
tein (NP365-380), which was originally identified by Townsend
as the major antigenic epitope of this virus in H-2
 
b
 
 mice. Wild-
type (WT) C57BL6/j mice were purchased from Jackson Labora-
tories (Bar Harbor, ME). CD28-deficient mice (39), backcrossed
to C57BL/6j for six generations, were kindly provided by Dr.
Tak Mak (University of Toronto, Toronto, Canada).
 
Production of Mice with a Targeted Mutation of the
HSA or both HSA and CD28
 
Mice Homozygous for a Disrupted HSA Gene.
 
The disruption of
the HSA gene in C57BL/6 ES line BL/6-III (50) was achieved
by replacement of the HSA promotor and the first exon with a
neomycin-resistance expression cassette. Southern blot analysis of
HSA-genotypes was performed using the DNA isolated from
mouse tail as described (51). The Pvu II fragment located be-
tween nucleotides 
 
2
 
710 and 
 
2
 
1790 relative to the transcrip-
tional start site of the HSA gene was used as a hybridization
probe.
 
Mice Deficient for both HSA and CD28.
 
A male CD28-deficient
mouse (a mixture of 129 and C57BL/6 backgrounds) was mated
to female HSA-deficient mice (strain C57BL/6). F1 offspring
were mated to HSA-deficient mice (also C57BL/6) and the re-
sulting HSA-deficient, CD28 heterozygote offspring were inter-
bred to generate HSA/CD28 double deficient mice.
 
Immunization and Antibody Treatment
 
C57BL/6j mice (WT) and mice with targeted mutations of
HSA and/or CD28 genes were injected with 1,000 HAU of in-
fluenza virus A/JAP intravenously (i.v.) or intraperitoneally (i.p.).
In some experiments, these mice were injected with either a mix-
ture of normal hamster and rat Ig or a mixture of anti-B7-1 and
anti-B7-2 at the doses and intervals given in the figure legends.
Spleen cells were harvested after immunization and antibody
treatments. The cytotoxicity of the freshly isolated spleen cells
were defined as the primary CTL response.
 
Evaluation of Memory CTL Responses
 
Three different assays were used to evaluate the activity of
memory T cells.
 
Recall Response in 96-Well Microplate Culture without Exogenous
Growth Factors.
 
Varying numbers of A/JAP-primed spleen cells
were restimulated in vitro with irradiated A/JAP-infected synge-
neic spleen cells (3 
 
3 
 
10
 
4
 
/well) for 5 d at 37
 
8
 
C in Click’s EHAA
medium containing 5% FCS. At the end of culturing, the cells
were washed twice with medium, the 
 
51
 
Cr-labeled target cells
were added and CTL activity was determined by 
 
51
 
Cr-release.
 
Bulk Culture.
 
When CD28-deficient spleen cells are used,
the recall CTL response in microplate culture is usually very weak,
so the priming of CTL in experiments involving CD28-KO T cells
were evaluated in bulk culture. In brief, pooled spleen cells from
groups of 2–3 mice were harvested on day 7 after i.v. or i.p. in-
jection of A/JAP (1,000 HAU) and were restimulated with A/JAP-
infected (1,000 HAU/12
 
 3 
 
10
 
6
 
 cells, 37
 
8
 
C,1 h), irradiated syngeneic
spleen cells for 5 d (Responder: stimulator ratio 5:1, with re-
sponder cells at a density of 10
 
6
 
/ml). At the end of culturing, viable
cells were harvested and the cytotoxicity of these cells was deter-
mined by a 6 h 
 
51
 
Cr-release assay.
 
Limiting Dilution Analysis.
 
Spleen cells were harvested from
either naive mice or mice that have been immunized with A/JAP
virus 5–7 wk previously. Graded numbers of spleen cells (pooled
from 2 mice per group, 24 wells replicates at each cell density)
were stimulated with A/JAP-infected, irradiated spleen cells. Su-
pernatants from PMA-activated EL4 cells were added at the be-
ginning of the culture at a final concentration of 1%. After 6 d of
culture, the plates were washed once with medium. 
 
51
 
Cr-labeled,
NP
 
366-374
 
-pulsed EL4 cells were added at 10
 
4
 
/well. The wells that
have given equal or greater than mean plus 3
 
3
 
 SD of medium re-
lease were scored as positive. The precursor frequency is calcu-
lated based on Poisson distribution.
 
Evaluation of Effector T Cells
 
In brief, syngeneic H-2
 
b
 
 EL4 cells were pulsed with (EL4-NP)
or without (EL4) 10 
 
m
 
g/ml of synthetic peptides corresponding 
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to AA 365–380 of influenza virus A/JAP nucleoprotein and la-
beled with 
 
51
 
Cr for 1 h at 37
 
8
 
C. The labeled target cells were
then incubated with the effector cells for 6 h, and the released
 
51
 
Cr in the supernatants were determined. The specific lysis per-
centages were calculated by the following formula:
Spleen cells freshly isolated from the animals 6–8 d after viral
infection were defined as primary effectors, and the CTL gener-
ated from primed spleen cells were defined as secondary effectors.
 
Results
 
Production of Mice Deficient for HSA and for both HSA and
CD28.
 
The disruption of the gene for the HSA in C57-
BL6ES line BL/6-III (50) was achieved by replacing the
HSA promotor and the first exon with a neomycin-resistance
expression cassette (Fig. 1 
 
a
 
). Except for a somewhat re-
duced litter size, the mice homozygous for the targeted
mutation (HSA-KO) (Fig. 1 
 
b
 
) are indistinguishable from
WT control in a conventional mouse facility. We have
mated HSA-deficient mice with previously developed CD28-
deficient mice and generated mice which are deficient in
both HSA and CD28. As shown in Fig. 2, normal numbers
of CD4 and CD8 T cells are generated in mice deficient
for either HSA and/or CD28. Furthermore, the major
types of APC, such as B cells, macrophages, and dendritic
cells, are produced in normal numbers in all mutant mice.
Thus, these mice can be used for studying the role of co-
stimulatory molecules in the generation effector and mem-
ory T cells.
 
B7, but not HSA, Is Required for the Induction of Effector T
Cells from Naive T Cells.
 
C57BL6/j mice infected with in-
fluenza virus mount a primary CTL response which is de-
Specific lysis %
cpmsamples cpmmedium – ()
cpmmaximum cpmmedium – ()
--------------------------------------------------------- 100. ´ =
 
tectable on day 5, which peaks at day 7 or 8, and disappears
within 2 wk after infection (1). In A/JAP (H2N2)-infected
H-2
 
b
 
 mice, the major antigenic epitope is NP365-380 of
A/JAP virus (52); the minimal peptide was later identified
as NP366-374 (53). We therefore used NP365-380-pulsed
EL4 cells to detect the primary CTL response.
As shown in Fig. 3, WT and HSA-deficient mice mount
a significant primary CTL response against NP-peptide-
pulsed syngeneic EL4 target cells, but not against unpulsed
EL-4, (Fig. 3, 
 
a
 
 and 
 
b
 
), or peptide-pulsed allogeneic P815
(H-2
 
d
 
) targets (data not shown). The kinetics of the CTL
response is similar in all mice
 
 
 
(data not shown). Although
in this experiment, the primary CTL response in HSA-
deficient mice is somewhat lower than WT mice, in other
experiments, HSA-KO mice appear to mount a higher pri-
mary CTL response (data not shown). Thus HSA is not re-
quired for the generation of primary CTL. In contrast, no
virus-specific primary CTL response is detected in mice
deficient for either CD28, or both CD28 and HSA, al-
though in some experiments, a significant nonspecific cyto-
toxicity was detected in CD28-deficient mice, most likely
due to NK cells. This lack of CTL response was not due to
a change in the kinetics, since we have been unable to de-
Figure 1. Production of mice homozygous for a disrupted HSA gene.
(a) The disruption of the HSA gene in C57BL/6 ES line BL/6-III was
achieved by replacement of the HSA promotor and the first exon with a
neomycin-resistance expression cassette. The coding portions of both
HSA exons are depicted by filled boxes. (b) Southern blot analysis of HSA
genotypes using a Pvu II fragment located between nucleotides 2710,
and 21790 relative to the transcriptional start site of the HSA gene as a
hybridization probe.
Figure 2. Mice with targeted mutations of HSA and/or CD28 produce
normal numbers of T cells, B cells and APC. Mouse spleen cells were an-
alyzed by flow cytometry after staining with either anti-HSA (20C9),
anti-CD28 (37N), anti-Mac-1 (TIB128), anti-dendritic cell (HB224),
FITC-labeled anti-CD4, and phycoerythrin-labeled anti-CD8 mAbs.
CD4, CD8, CD28, B220, and HSA typing was done with freshly isolated
spleen cells in pools from three mice. Expression of CD28 on gated T
cells is presented. Macrophage and dendritic cells were determined using
low-density spleen cells, enriched by centrifugation over a 55% Percoll
medium. The genotypes and antibodies used are marked on the panels. 
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tect primary responses against influenza virus between day
3 and day 14, in mice with a targeted mutation of CD28
(data not shown). Because CD28 is the major receptor for
the costimulatory molecules B7-1/2, these results strongly
suggest that B7 is necessary for the induction of primary
CTL. This is more directly demonstrated by the results in
Fig. 4, which show that a mixture of anti-B7-1/B7-2 com-
pletely eliminates the primary anti-influenza NP CTL re-
Figure 3. Primary in vivo
CTL response against influenza
virus in WT mice (a), and mice
with a targeted mutation of HSA
(b), CD28 (c), or of both HSA
and CD28 (d). Spleen cells were
harvested from mice on day 7 af-
ter A/JAP-infection. The CTL
activities were tested on either
peptide (AA365-380 of the nu-
cleoprotein from A/JAP virus)-
pulsed (EL4-NP), or unpulsed
EL4 cells (EL4). Representatives
of three independent experi-
ments using pooled spleen cells
from 2–4 mice in each group are
shown.
Figure 4. Anti-B7 mAbs
completely block the produc-
tion of effector CTL from naive
T cells in both WT mice (a) or
HSA-KO (b) mice. WT and mu-
tant mice were infected with
1,000 HAU/mouse of influenza
virus A/JAP by intraperitoneal
injection on day 0. The mice
were injected with either a mix-
ture of normal rat and hamster
IgG, or anti-B7-1 1 anti-B7-2
mAbs (3A121GL1) on days 21,
0,  11, at a dose of 100 mg/
mouse/injection. Data presented
are representative of three exper-
iments using pooled spleen cells
from 2–3 mice per group. 
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sponse in both WT and HSA-deficient mice. In contrast,
anti-HSA mAb 20C9 does not block primary effector CTL
responses (data not shown). These results also demonstrate
that anti-B7 mAbs efficiently block the function of B7 in
vivo. 
 
Two Costimulatory Pathways for Rapid Priming of Recall
CTL Response In Vitro.
 
Infection of mice with influenza
virus primes a recall CTL response in vitro, detectable as
early as 48 h after infection (our unpublished results). To
test the requirement for costimulatory molecules in the
priming of the recall CTL response, we infected WT and
HSA-KO mice with influenza virus either in the presence
or absence of antibodies to B7 or HSA. After 8 d, spleen
cells were restimulated in vitro for 5–6 d with influenza vi-
rus-infected syngeneic spleen cells in the absence of mAbs
and CTL activity was measured. Fig. 5 
 
a
 
 shows that the re-
call response requires in vivo priming.
 
 
 
In the WT mice,
the recall responses were not affected by treatment with a
mixture of anti-B7-1 and anti-B7-2 antibodies during prim-
ing (Fig. 5 
 
b
 
). In contrast, a mixture of anti-B7-1/B7-2 to-
tally abolished the priming in the HSA-KO mice (Fig. 5 
 
b
 
).
The efficacy of the anti-B7 mAbs in vivo is confirmed be-
cause such treatment completely eliminated primary CTL
response in vivo in both WT and HSA-deficient mice (Fig.
4). Thus, costimulation by either B7 or HSA is required for
the in vivo priming of the recall CTL response.
Several recent studies demonstrated that T cells can be
primed in mice with a targeted mutation of CD28 (CD28-
KO) (39), or transgenic for CTLA4-Ig (which very effec-
tively blocks the interaction of B7-1 and B7-2 with CD28
and CTLA4) (40). To test whether costimulation by HSA
accounts for this priming, we injected anti-HSA mAb into
CD28KO mice. As shown in Fig. 6, the recall CTL re-
sponse generated in CD28KO mice was inhibited almost
completely by pre-treatment with anti-HSA during prim-
ing. In contrast, the priming to influenza virus in WT mice
was not significantly affected by anti-HSA mAb. These re-
sults demonstrate that the targeted mutation of CD28 ren-
ders the CTL priming more dependent on costimulation
by HSA.
To substantiate this conclusion, we have produced mice
with targeted mutations of both the HSA and the CD28
genes (Fig. 2) and compared the recall CTL responses in
mice with targeted mutations of HSA and/or CD28. In-
deed, recall CTL response in mice deficient for both CD28
and HSA was 
 
z
 
100-fold lower than that in the WT mice
(Fig. 6 
 
c
 
). CD28-deficiency leads to 
 
z
 
3–5-fold reduction
of recall CTL responses, while HSA-deficient mice mount
normal recall CTL responses (Fig. 6 
 
c
 
). The relative contri-
bution of HSA- and CD28-mediated costimulation in T
cell priming, however, cannot be determined by this ex-
periment, because the CD28:B7 pathway is also required
for optimal recall responses (see below). The observed re-
duction in recall CTL response in CD28-deficient mice
Figure 5. Requirement of co-
stimulatory molecules for the
generation of primed T cells as-
sayed at 8 d after priming: micro-
plate culture in the absence of ex-
ogenous cytokines. (a) Anti-viral
CTL of in vitro-stimulated spleen
cells from either naive or A/JAP-
primed mice. (b) Requirement of
B7 family members for the genera-
tion of primed T cells. WT and
HSA-KO mice were infected with
1,000 HAU/mouse of influenza
virus A/JAP by intraperitoneal in-
jection on day 0. On days 21, 0,
11, these mice were injected with
either a mixture of normal rat and
hamster IgG, or anti-B7-1 1 anti-
B7-2 mAbs (3A121GL1) at a dose
of 100 mg/mouse/injection. Spleen
cells were harvested 8 d after viral
infection and were restimulated with
irradiated, A/JAP-infected synge-
neic spleen cells for 6 d in vitro,
and CTL activity determined. Re-
sponder cells used were from pools
of two spleens. Data in b were lysis
of NP peptide (AA365-380)-pulsed
EL4 target (104/well) only. The
lysis of unpulsed EL4 cells is not
shown but was always less than
10%. Representative of three ex-
periments, with two mice per
group are shown. 
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could also be attributed to a role of CD28 in the generation
of effector from the primed T cells.
 
Induction of Memory from Naive T Cells Requires Costimula-
tion by Either B7 or HSA.
 
T cells responsible for long-term
memory may be different from those for the early recall
response measured here (54, 55). Since the above experi-
ments used spleen cells that were primed only 8 d previ-
ously, we treated both WT and HSA-KO mice with anti-B7
mAbs for 3 wk and waited 100 d after immunization before
harvesting spleen cells and assaying for memory cells in an
in vitro recall culture. As shown in Fig. 7, while repeated
treatment with anti-B7 mAbs reduced the recall CTL ac-
tivity in the WT mice, there still were very potent recall
CTL responses in such anti-B7-treated mice. In fact, the
numbers of responder cells required for detectable recall re-
sponses in vitro were similar in both groups. In contrast, in
HSA-KO mice, injection of a mixture of anti-B7 mAbs
eliminated the generation of memory cells. These results
demonstrate that costimulation by either B7 or HSA alone
is sufficient for induction of memory T cells, regardless of
when the memory activity is determined. The lack of long-
term memory in anti-B7 treated HSA-KO mice rules out
the possibility that memory cells are produced after decay
of the antibodies in vivo. Moreover, the production of
memory cells in anti-B7-treated WT mice depends on
HSA. Thus, the induction of T cells responsible for rapid
priming of recall CTL responses and long-term memory
responses has a similar requirement for costimulatory mole-
cules; either B7 or HSA can provide costimulation for in-
duction of memory T cells.
We have also measured the frequency of the precursors
for NP
 
366-374
 
-specific cytotoxic T cells by limiting dilu-
tions. As shown in Table 1, naive WT, HSA-KO, CD28-
KO, and CD28/HSA-KO mice have a similar number of
NP-specific CTLp in the spleen. These results support the
notion that T cell development is not grossly affected by
targeted-mutation of HSA and/or CD28. 5–7 wk after vi-
ral infection, the CTLp is increased by 10–50-fold in WT
mice and in mice deficient for either HSA or CD28, al-
though targeted mutation of CD28 reduced the expansion
of CTLp. Most importantly, no significant increase of
CTLp can be detected after mice deficient for both HSA
and CD28 are infected with influenza virus. These results
demonstrated that one costimulatory pathway, mediated by
either HSA or CD28, is necessary and sufficient for in-
crease of the CTLp during induction of immunological
memory.
 
B7, but not HSA, Is Required for the Generation of Effector
CTL from Memory T Cells.
 
The activation of memory T
cells gives rise to effector T cells. To test whether this pro-
cess requires costimulatory molecules, we stimulated primed
spleen cells in the presence of mAb against either B7 or
HSA. As shown in Fig. 8 
 
a
 
, for spleen cells primed when
both B7 and HSA-costimulation pathways are intact, the
recall response requires costimulation by B7, but not the
HSA. To test whether priming conditions affect the re-
quirement for costimulatory molecules in eliciting effector
Figure 6. Either HSA or CD28-mediated costimulation is sufficient for
generation of primed T cells: bulk cultures. (a and b) Anti-HSA mAb
20C9 blocks T cell memory in CD28KO (b) but not WT mice (a), as
measured by recall CTL responses in vitro. CD28-deficient mice and syn-
geneic WT mice were treated with either normal hamster Ig or anti-HSA
mAb (300 mg/mouse/injection) on day 21, day 0, and day 1. On day 0,
these mice were injected intraperitoneally with influenza virus A/JAP
(1,000 HAU/mouse), spleen cells were harvested on day 7; and were re-
stimulated with A/JAP-infected (1,000 HAU/12 3 106 cells, 378C,1 h),
irradiated syngeneic spleen cells for 5 d (responder: stimulator ratio 5:1,
with responder cells at a density of 106/ml). At the end of culturing, via-
ble cells were harvested and the cytotoxicity of these cells was determined
by a 6 h 51Cr-release assay. (c) Recall CTL responses in mice with differ-
ent targeted mutations. The pooled spleen cells from groups of 2–3 mice
were harvested on day 7 after i.v. injection of A/JAP (300 HAU), recall
CTL activity determined as in a and b. Representatives of 2–3 indepen-
dent experiments are shown. Note overall CTL responses in c are stron-
ger than in a and b due to a stronger priming via i.v. injection. Dashed
lines are the lysis of EL-4 cells in the absence of NP peptide.257 Liu et al.
CTL from memory T cells, spleen cells primed when B7 or
HSA was blocked were restimulated in the presence of
anti-HSA or anti-B7 mAbs. Again, T cells primed in the
absence of costimulation by either B7 or HSA require co-
stimulation by B7 for a recall response (Fig. 8, b and c). No
recall CTL can be detected in microculture when both B7
and HSA are blocked during priming (Figs. 4 and 8 d).
Thus, regardless of the priming conditions, B7 but not
HSA is essential for eliciting effector from memory T cells.
Discussion
A critical issue pertinent to the basis of self-nonself dis-
crimination in the immune system is whether induction of
immunological memory requires costimulation, in addition
to antigen. The two-signal theory of T cell activation (9–13)
argues that stimulation of naive T cells in the absence of
costimulation leads to tolerance rather than immunological
memory. Classical experiments using either fixed APC (56)
or transplantation of cultured allogeneic or xenogeneic en-
docrine grafts (57) indicate that immunological tolerance is
induced when costimulatory activity is eliminated, either
by depletion or by inactivation of resident APC. Recently,
it has been documented that blocking the B7-CD28/
CTLA4 interaction leads to tolerance rather than immunity
to xenogeneic grafts (38). However, several more recent
experiments designed to test the requirement of B7:CD28/
CTLA4 interaction in the induction of memory T cells do not
support an essential role of B7 family members in the in-
duction of immunological memory. Thus, transgenic mice
which constitutively express a high level of CTLA4Ig, a fu-
sion protein consisting of the high affinity B7 receptor
Figure 7. Requirement for co-
stimulatory molecules in the genera-
tion of memory T cells assayed at
100 d after priming: microplate cul-
ture in the absence of exogenous cy-
tokines. Both WT and HSA-KO
mice were injected with influenza
virus A/JAP (1,000 HAU/mouse)
(day 0) and treated with either a
mixture of hamster and rat Ig or a
mixture of anti-B7-1 plus B7-2 on
days  21, 1, 3, 7, 10, 13, 21 (200 mg/
mAb/injection). At 100 d after the
viral infection, pooled spleen cells
(three mice per group) were stimu-
lated in vitro, CTL activity was de-
termined 5 d after stimulation. Similar
results were obtained when memory
CTL activity was measured at 30 d
after infection.
Table 1. Numbers of the Precursors for NP366-374-specific 
Cytotoxic T Cells Per Million of Spleen Cells as Measured by 
Limiting Dilution*
Mouse strains Naive
Primed‡
Fold of
increase
i.v. i.p. i.v. i.p.
C57BL/6j 1.47 71.0 74.1 48.3 50.4
HSA(2/2) 2.44 45.0 90.9 18.4 37.3
CD28(2/2) 1.25 30.3 13.5 24.2 10.8
CD28(2/2) HSA(2/2) 2.80 6.2 3.92 2.2 1.4
*Graded numbers of cells (24 replicates at each density) from either na-
ive or primed mice (2 mice per group) were stimulated in vitro with
105/well of A/JAP-infected, irradiated spleen cells from syngeneic
C57BL/6j mice in the presence of T cell growth factors (PMA-acti-
vated EL4 cell supernatants used at 1% final concentration) for 6 d. The
number of precursor cells was calculated by Poisson distribution.
‡Spleen cells were taken from mice immunized with 1,000 HAU/
mouse, either intravenously (i.v. used 5 wk after immunization) or in-
traperitoneally (i.p., 7 wk after immunization).258 Costimulation for Immunological Memory
CTLA4 fused to the immunoglobulin Fc portion, show an
even better priming than the littermate controls (40). In
addition, fibroblasts transfected with viral glycoproteins in-
duce successful priming in the absence of B7 expression
(41). Because the B7:CD28 interaction is not essential, it
has been proposed that induction of T cell memory does
not require costimulation.
Given the fact that several costimulatory molecules have
been discovered, we were interested in testing whether a
lack of requirement for B7 in the induction of immunolog-
ical memory was due to the existence of other redundant
costimulatory pathways. We have used three different as-
says to measure the memory CTL response. The first is a
microplate restimulation culture in the absence of exoge-
nous cytokines. Such assay allows us to estimate the num-
ber of spleen cells necessary to generate a detectable CTL
response (presumably including helper and CTLp). The
second assay is a bulk culture involving a larger number of
cells (10 3 106 cells in 10 ml). Whereas this assay is per-
ceived to be less quantitative than the first assay, it is more
sensitive and appears to be the only assay that allows detec-
tion of optimal recall CTL response in spleen cells from
CD28-deficient mice without adding exogenous cytokines.
Most likely, this is due to the involvement of CD28 in elic-
iting CTL from memory cells. Thirdly, we have used a
limiting dilution assay to measure the precursor frequency
of NP366-374-specific CTL. This method is widely used to
measure CTL memory, however, it should be noted that
this assay only measures the persistency of expanded CTL.
Utilization of three different assays allows a more compre-
hensive measurement of the memory CTL response.
We show here that in mice with a targeted-mutation of
the HSA gene, but not in the WT mice, B7 is required for the
induction of immunological memory. In contrast, in CD28-
deficient mice, the HSA is necessary for T cell priming.
Memory T cell response is hardly detectable in mice defi-
cient for both HSA and CD28. Thus, induction of immu-
nological memory requires costimulation, but either B7
family members or the HSA are sufficient. It should be
noted that while our studies have stressed the importance
of costimulation mediated by either HSA or CD28. We
cannot rule out contribution of other costimulatory mole-
cules in the induction of memory T cells. In this regard, it
is worth noting that blockade of both CD40L:CD40 and
CD28/CTLA4:B7 interactions is more efficient than sim-
ply blocking either one in preventing clonal expansion of
Figure 8. B7, but not HSA, plays an important role in the induction of effector T cells from memory T cells, regardless of the priming conditions: micro-
plate culture in the absence of exogenous cytokines. Spleen cells from either WT (a and b) or HSA-deficient mice (c and d) pretreated with either normal Ig
(a and c) or a mixture of anti-B7-1 and anti-B7-2 (b and d) were infected with A/JAP virus as detailed in the legend to Fig. 3. Increasing numbers of
spleen cells were stimulated in vitro for 5 d with A/JAP-infected spleen cells, in the presence of either medium, or a mixture of anti-B7-1 and anti-B7-2, or
anti-HSA mAb (final concentration at 5 mg/ml), and CTL activity was determined in a 6-h 51Cr-release assay. Representative of three independent ex-
periments are shown. Similar results were obtained when memory activity is measured in bulk cultures.259 Liu et al.
self-reactive helper T cells (58). It is likely that CD40L-
induced costimulatory molecules, such as CD44 (59) and
ICAM-1 (60) may participate in induction of memory T cells.
It is worth noting that targeted mutation of CD28 alone
causes a three- to fivefold reduction in recall CTL re-
sponse, while HSA-deficiency alone is not sufficient to af-
fect immunological memory (Fig. 6). These results may in-
dicate that CD28-dependent costimulatory pathway is more
important than that of HSA for induction of memory CTL.
However, since memory cells are quantitated by the effec-
tor T cells they produced, and since production of effector
cells from memory cells requires B7 (Fig. 8), the reduction
in recall CTL response may be due to lack of CD28 on the
memory cells. In this regard, it is worth noting that trans-
genic expression of CTLA4Ig, which blocks B7:CD28/
CTLA4 interaction, does not affect induction of immu-
nological memory when it is assayed in the absence of
CTLA4Ig (40). Similarly, priming in the presence of anti-
B7 mAbs does not affect induction of recall response (Fig.
5). In contrast, since HSA is not involved in the induction
of effector T cells from memory T cells (Fig. 8), a reduc-
tion in recall response caused by targeted mutation of HSA
can be attributed to HSA involvement during priming.
An important conclusion of our study is that distinct co-
stimulatory molecules can be utilized in the induction ef-
fector and memory T cells. Induction of effector T cells
depends strictly on costimulation by B7, while induction of
memory T cells requires costimulation by either B7 or the
HSA. These conclusions are based on three lines of evi-
dence. First, a mixture of anti-B7-1 and anti-B7-2 mAb
completely blocks the generation of primary CTL response
in WT mice, yet it does not seem to significantly affect the
generation of memory CTL responses. While the magni-
tude of the recall response was affected somewhat in the
long-term memory response, the number of memory cells
was not altered. Second, a targeted mutation of CD28
eliminates the antigen-specific primary CTL responses, yet
it causes only a small reduction in the number of precursor
cells at 5–7 wk after priming. Third, costimulation by HSA
plays no role in the induction of effector T cells from either
naive or memory T cells, yet it provides an alternative co-
stimulatory pathway for the induction of memory T cells.
That HSA enhances priming CTL responses is supported
by a recent study in which transfection of HSA into tumor
cells lead to enhanced memory CTL response (28).
Because CD4 T cells can provide help for CD8 T cell
responses in both priming and induction of effector from
memory T cells, our results could be explained on the basis
of a requirement for costimulation in the CD4 T cell com-
partment. However, previous studies from others and us
have demonstrated that, in an anti-influenza CTL response,
induction of memory T cells is independent of CD4 T cells
(61, 62). Blocking the priming of CD4 T cells, therefore,
cannot lead to a defect of CD8 T cell response as reported
here. Furthermore, we demonstrate here that targeted mu-
tation of both CD28 and HSA prevents clonal expansion of
CTLp (Table 1).
A simple model can be proposed to explain the require-
ment for distinct but overlapping costimulatory molecules in
the induction of effector and memory CTL. The strength
of the total signals received by naive T cells could deter-
mine whether they will differentiate into effector or mem-
ory T cells. A stronger stimulation (integration of signals
from TCR and costimulation) would lead to the produc-
tion of effector cells, while a weaker stimulation would be
sufficient to produce memory cells. HSA is a less potent
costimulatory molecule for clonal expansion of T cells than
B7 family members, so it can only be utilized for the in-
duction of a memory T cell responses. B7, being a stronger
costimulator, can be used for both memory and effector T cell
responses, depending on the concentration of the molecule
on the surface of APC and the strength of the TCR/anti-
gen interaction. For example, dendritic cells, which express
a high level of B7, may induce the production of effector T
cells, while B cells, which express a lower level of B7, may
be more likely to induce only memory T cells.
Our study may explain the interesting difference be-
tween viruses regarding the requirement for the costimula-
tory receptor CD28 in the induction of CTL in vivo. Shi-
hanian et al. (39), showed that CD28 is not required for
induction of CTL specific for lymphocytic choriomeningi-
tis virus (LCMV) in vivo. Since LCMV causes a productive
infection in mice, naive T cells can first be primed, and
then these primed T cells can give rise to effector CTL af-
ter repeated stimulation. The influenza virus used in this
Figure 9. A model for the involvement of costimulatory signals in the
generation of effector and memory T cells. Two major products, effector
and memory T cells, are produced from naive T cells after viral infection.
The production of memory T cells requires costimulation by either HSA
or B7, while the production of effector T cells utilizes B7 but not HSA.
By definition, memory T cells give rise to effector T cells after further
stimulation by antigen. However, effector T cells are unlikely to be man-
datory precursors for memory T cells and distinct costimulatory molecules
could be used at different phases of the immune response.260 Costimulation for Immunological Memory
study, and the vesicular stomatitis virus used by Kündig et al.,
do not cause productive infection, and thus the CTL re-
sponse in vivo become CD28-dependent after one round
of infection (63). 
A successful adaptive immune response has two major
T cell products: effector T cells and memory T cells. The
lineage relationship between these two types of cells has not
been resolved. Because effector T cells and memory T cells
share certain activation conditions (64) and express several
identical activation markers (65), it has been proposed that
memory T cells are derived from effector T cells (55, 64,
65). A critical prediction of this hypothesis is that memory
T cell responses should be eliminated when the effector T cell
responses are abrogated. Results presented in this study
show that memory CTL responses are largely intact when
effector T cell development is completely absent. These re-
sults are not consistent with the notion that effector T cells
are mandatory precursors for memory T cells. Further-
more, we showed that costimulation by HSA does not
contribute to generation of effector cells, but it can and
does contribute to the generation of memory cells. This
qualitative difference in costimulatory molecules used for
effector vs memory T cell responses strongly suggests that
these two types of cells can be products of different activa-
tion pathways (see Fig. 9 for a model).
A critical test for the model is whether memory cells can
be produced when effector T cells are ablated. A major ob-
stacle to such a test is that memory and effector T cells are
traditionally measured at different times after antigenic
stimulation. Effector CTL disappears within two weeks af-
ter influenza viral infection, yet memory cells are generally
measured long after that. This is necessary not because of
the kinetics of production of memory, since elegant studies
demonstrated that T cell memory is produced as early as
three days after antigen challenge (66); rather, it is because
of the need to differentiate memory from effector cells.
Since blocking B7 or CD28 efficiently eliminates produc-
tion of effector T cells, we can use the same spleen cells to
test whether priming can take place when effector CTL are
not generated. Such an analysis strongly supports the no-
tion that the primed T cells are not derived from effector
T cells. Experiments are under way to test whether the ac-
tivity measured in this early recall assay represents true im-
munological memory.
In conclusion, we have produced mice with a targeted
mutation of HSA, and mice deficient for both HSA and
CD28. We have demonstrated that the induction of mem-
ory T cells requires costimulation by either B7 or HSA,
while induction of effector T cells depends on B7 but not
HSA. Our study firmly establishes that induction of immu-
nological memory requires costimulation, and that either
B7 or HSA is sufficient for this step. It also raises an inter-
esting possibility that memory T cells can be induced with-
out going through an effector phase.
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